{"id":3529,"date":"2020-06-09T09:00:34","date_gmt":"2020-06-09T09:00:34","guid":{"rendered":"https:\/\/cn-bio.com\/?p=3529"},"modified":"2022-08-19T07:02:28","modified_gmt":"2022-08-19T07:02:28","slug":"cn-bio-and-cambridge-university-identify-novel-regulatory-pathway-driving-nash","status":"publish","type":"post","link":"https:\/\/cn-bio.com\/cn-bio-and-cambridge-university-identify-novel-regulatory-pathway-driving-nash\/","title":{"rendered":"CN Bio and Cambridge University identify novel regulatory pathway driving NASH"},"content":{"rendered":"<ul>\n<li data-leveltext=\"\uf0b7\" data-font=\"Symbol\" data-listid=\"4\" aria-setsize=\"-1\" data-aria-posinset=\"1\" data-aria-level=\"1\"><i><span data-contrast=\"none\">Paper published in Nature Metabolism&nbsp;<\/span><\/i><i><span data-contrast=\"none\">demonstrates&nbsp;<\/span><\/i><i><span data-contrast=\"none\">novel pathway regulating the underlying mechanism of liver fibrosis<\/span><\/i><span data-ccp-props=\"{&quot;134233279&quot;:true,&quot;201341983&quot;:0,&quot;335559740&quot;:276}\">&nbsp;<\/span><\/li>\n<li data-leveltext=\"\uf0b7\" data-font=\"Symbol\" data-listid=\"4\" aria-setsize=\"-1\" data-aria-posinset=\"2\" data-aria-level=\"1\"><i><span data-contrast=\"none\">Research&nbsp;<\/span><\/i><i><span data-contrast=\"none\">harnesses<\/span><\/i><i><span data-contrast=\"none\">&nbsp;CN&nbsp;<\/span><\/i><i><span data-contrast=\"none\">Bio\u2019s&nbsp;<\/span><\/i><i><span data-contrast=\"none\">liver-on-chip&nbsp;<\/span><\/i><i><span data-contrast=\"none\">NASH disease model<\/span><\/i><i><span data-contrast=\"none\">,<\/span><\/i><i><span data-contrast=\"none\">&nbsp;to&nbsp;<\/span><\/i><i><span data-contrast=\"none\">advance development of&nbsp;<\/span><\/i><i><span data-contrast=\"none\">potential&nbsp;<\/span><\/i><i><span data-contrast=\"none\">n<\/span><\/i><i><span data-contrast=\"none\">ew medicines&nbsp;<\/span><\/i><i><span data-contrast=\"none\">for&nbsp;<\/span><\/i><i><span data-contrast=\"none\">liver fibrosis<\/span><\/i><span data-ccp-props=\"{&quot;134233279&quot;:true,&quot;201341983&quot;:0,&quot;335559740&quot;:276}\">&nbsp;<\/span><\/li>\n<\/ul>\n<p><span data-contrast=\"none\">CN Bio, <\/span><span data-contrast=\"none\">a leading&nbsp;<\/span><span data-contrast=\"none\">cell culture<\/span><span data-contrast=\"none\">&nbsp;company that has developed&nbsp;<\/span><span data-contrast=\"none\">single and multi-organ microphysiological systems (MPS) that improve the accuracy and efficiency of drug discovery<\/span><span data-contrast=\"none\">,&nbsp;<\/span><span data-contrast=\"none\">today announced&nbsp;<\/span><span data-contrast=\"none\">the publication of&nbsp;<\/span><span data-contrast=\"none\">co-authored&nbsp;<\/span><span data-contrast=\"none\">research led by researchers at the University of Cambridge in Nature Metabolism<\/span><span data-contrast=\"none\">1<\/span><span data-contrast=\"none\">,&nbsp;<\/span><span data-contrast=\"none\">identifying&nbsp;<\/span><span data-contrast=\"none\">a novel pathway that regulates the underlying mechanism of Non-Alcoholic Steatohepatitis (NASH),&nbsp;<\/span><span data-contrast=\"none\">potentially a new&nbsp;<\/span><span data-contrast=\"none\">therapeutic target. The&nbsp;<\/span><span data-contrast=\"none\">collaborative&nbsp;<\/span><span data-contrast=\"none\">work&nbsp;<\/span><span data-contrast=\"none\">uses CN Bio\u2019s NASH&nbsp;<\/span><span data-contrast=\"none\">model&nbsp;<\/span><span data-contrast=\"none\">to<\/span><span data-contrast=\"none\">&nbsp;help<\/span><span data-contrast=\"none\">&nbsp;<\/span><span data-contrast=\"none\">elucidate<\/span><span data-contrast=\"none\">&nbsp;the complex cellular mechanisms that cause liver fibrosis.<\/span><span data-ccp-props=\"{&quot;201341983&quot;:0,&quot;335559740&quot;:276}\">&nbsp;<\/span><\/p>\n<p><span data-contrast=\"none\">The group&nbsp;<\/span><span data-contrast=\"none\">demonstrated that&nbsp;<\/span><span data-contrast=\"none\">Bone Morphogenetic Protein 8<\/span><span data-contrast=\"none\">B<\/span><span data-contrast=\"none\">&nbsp;(BMP8B),&nbsp;<\/span><span data-contrast=\"none\">a poorly characteri<\/span><span data-contrast=\"none\">s<\/span><span data-contrast=\"none\">ed member<\/span><span data-contrast=\"none\">&nbsp;<\/span><span data-contrast=\"none\">of the BMP\/TGF\u03b2 superfamily<\/span><span data-contrast=\"none\">,&nbsp;<\/span><span data-contrast=\"none\">exhibits marked upregulation during Non-Alcoholic Fatty Liver Disease (N<\/span><span data-contrast=\"none\">AFLD<\/span><span data-contrast=\"none\">)&nbsp;<\/span><span data-contrast=\"none\">to NASH&nbsp;<\/span><span data-contrast=\"none\">disease progression<\/span><span data-contrast=\"none\">.<\/span><span data-contrast=\"none\">&nbsp;<\/span><span data-contrast=\"none\">T<\/span><span data-contrast=\"none\">his surge of BMP8B&nbsp;<\/span><span data-contrast=\"none\">was shown to be<\/span><span data-contrast=\"none\">&nbsp;<\/span><span data-contrast=\"none\">an important mediator of liver disease&nbsp;<\/span><span data-contrast=\"none\">progression, and&nbsp;<\/span><span data-contrast=\"none\">a leading pathogenic<\/span><span data-contrast=\"none\">&nbsp;<\/span><span data-contrast=\"none\">mediator of the wound healing response of NASH,<\/span><span data-contrast=\"none\">&nbsp;<\/span><span data-contrast=\"none\">therefore&nbsp;<\/span><span data-contrast=\"none\">presenting itself as&nbsp;<\/span><span data-contrast=\"none\">a potential therapeutic target<\/span><span data-contrast=\"none\">.<\/span><span data-ccp-props=\"{&quot;201341983&quot;:0,&quot;335559740&quot;:276}\">&nbsp;<\/span><span data-ccp-props=\"{&quot;201341983&quot;:0,&quot;335559740&quot;:276}\">&nbsp;<\/span><\/p>\n<p><span data-contrast=\"none\">Contributing organisation<\/span><span data-contrast=\"none\">s<\/span><span data-contrast=\"none\">&nbsp;include:<\/span><span data-contrast=\"none\">&nbsp;<\/span><span data-contrast=\"none\">University of Cambridge,&nbsp;<\/span><span data-contrast=\"none\">Newcastle University<\/span><span data-contrast=\"none\">, National &amp;&nbsp;<\/span><span data-contrast=\"none\">Kapodistrian<\/span><span data-contrast=\"none\">&nbsp;<\/span><span data-contrast=\"none\">University of Athens<\/span><span data-contrast=\"none\">,&nbsp;<\/span><span data-contrast=\"none\">Nordic Bioscience<\/span><span data-contrast=\"none\">&nbsp;A\/S, Sorbonne&nbsp;<\/span><span data-contrast=\"none\">Universit\u00e9<\/span><span data-contrast=\"none\">,&nbsp;<\/span><span data-contrast=\"none\">Imperial College London<\/span><span data-contrast=\"none\">&nbsp;and&nbsp;<\/span><span data-contrast=\"none\">Wellcome Trust<\/span><span data-contrast=\"none\">&nbsp;Sanger Institute<\/span><span data-ccp-props=\"{&quot;201341983&quot;:0,&quot;335559740&quot;:276}\">&nbsp;<\/span><\/p>\n<p><span data-contrast=\"none\">The paper&nbsp;<\/span><span data-contrast=\"none\">illustrates&nbsp;<\/span><span data-contrast=\"none\">the&nbsp;<\/span><span data-contrast=\"none\">direct&nbsp;<\/span><span data-contrast=\"none\">translation&nbsp;<\/span><span data-contrast=\"none\">between<\/span><span data-contrast=\"none\">&nbsp;<\/span><span data-contrast=\"none\">CN Bio\u2019s NASH assay<\/span><span data-contrast=\"none\">,<\/span><span data-contrast=\"none\">&nbsp;human clinical studies&nbsp;<\/span><span data-contrast=\"none\">and&nbsp;<\/span><i><span data-contrast=\"none\">in vivo<\/span><\/i><span data-contrast=\"none\">&nbsp;mouse models<\/span><span data-contrast=\"none\">. It demonstrates&nbsp;<\/span><span data-contrast=\"none\">that&nbsp;<\/span><span data-contrast=\"none\">the MPS NASH model<\/span><span data-contrast=\"none\">&nbsp;can<\/span><span data-contrast=\"none\">&nbsp;<\/span><span data-contrast=\"none\">offer more human-relevant data than standard liver tissue studies,<\/span><span data-contrast=\"auto\">&nbsp;<\/span><span data-contrast=\"auto\">and a quicker and cheaper option to study NASH pathophysiology with similar results to long and expensive animal models&nbsp;<\/span><span data-contrast=\"none\">to better inform the drug discovery process and reduce associated costs.&nbsp;<\/span><span data-contrast=\"none\">Cell cultures were performed in&nbsp;<\/span><span data-contrast=\"none\">CN Bio<\/span><span data-contrast=\"none\">\u2019s<\/span><span data-contrast=\"none\">&nbsp;<\/span><span data-contrast=\"none\">MPS&nbsp;<\/span><span data-contrast=\"none\">NASH model<\/span><span data-contrast=\"none\">,&nbsp;<\/span><span data-contrast=\"none\">utilis<\/span><span data-contrast=\"none\">ing its<\/span><span data-contrast=\"none\">&nbsp;proprietary liver-on-chip technology<\/span><span data-contrast=\"none\">,&nbsp;<\/span><span data-contrast=\"none\">which enables<\/span><span data-contrast=\"none\">&nbsp;longer term&nbsp;<\/span><i><span data-contrast=\"none\">in vitro<\/span><\/i><span data-contrast=\"none\">&nbsp;culture (&gt;1 month) of primary&nbsp;<\/span><span data-contrast=\"none\">human hepatocytes<\/span><span data-contrast=\"none\">&nbsp;in 3D microtissue structures. The NASH&nbsp;<\/span><span data-contrast=\"none\">assay<\/span><span data-contrast=\"none\">&nbsp;captures all key aspects of th<\/span><span data-contrast=\"none\">e&nbsp;<\/span><span data-contrast=\"none\">different stages of&nbsp;<\/span><span data-contrast=\"none\">the&nbsp;<\/span><span data-contrast=\"none\">NAFLD\/NASH spectrum<\/span><span data-contrast=\"none\">: intracellular fat accumulation, inflammation and fibrosis.<\/span><span data-contrast=\"none\">&nbsp;<\/span><span data-ccp-props=\"{&quot;201341983&quot;:0,&quot;335559740&quot;:276}\">&nbsp;<\/span><\/p>\n<p><b><span data-contrast=\"none\">Dr David Hughes,<\/span><\/b><b><span data-contrast=\"none\">&nbsp;CEO, CN Bio, commented: \u201c<\/span><\/b><i><span data-contrast=\"none\">I<\/span><\/i><i><span data-contrast=\"none\">ncreasing global levels of obesity are paralleled with&nbsp;<\/span><\/i><i><span data-contrast=\"none\">growing<\/span><\/i><i><span data-contrast=\"none\">&nbsp;<\/span><\/i><i><span data-contrast=\"none\">numbers of NASH patients. However, currently there are no therapies on the market to treat the disease, with candidates in phase 3 clinical trials not effective enough to treat the majority of patients<\/span><\/i><i><span data-contrast=\"none\">.<\/span><\/i><i><span data-contrast=\"none\">&nbsp;<\/span><\/i><i><span data-contrast=\"none\">By providing human-relevant&nbsp;<\/span><\/i><i><span data-contrast=\"none\">organ-on-chip<\/span><\/i><i><span data-contrast=\"none\">&nbsp;dat<\/span><\/i><i><span data-contrast=\"none\">a,<\/span><\/i><span data-contrast=\"none\">&nbsp;<\/span><i><span data-contrast=\"none\">our NASH model is&nbsp;<\/span><\/i><i><span data-contrast=\"none\">enabling researchers to screen new NAFLD and NASH therapeutic candidates, investigate mechanisms of action and generate actionable data in week<\/span><\/i><i><span data-contrast=\"none\">s, ultimately to fast-track investigation into new drug candidates.<\/span><\/i><i><span data-contrast=\"none\">\u201d<\/span><\/i><span data-ccp-props=\"{&quot;201341983&quot;:0,&quot;335559740&quot;:276}\">&nbsp;<\/span><span data-ccp-props=\"{&quot;201341983&quot;:0,&quot;335559740&quot;:276}\">&nbsp;<\/span><\/p>\n<p><b><span data-contrast=\"none\">Dr Tomasz Kostrzewski, Director, Biology, CN Bio, said<\/span><\/b><i><span data-contrast=\"none\">: \u201c<\/span><\/i><i><span data-contrast=\"none\">Th<\/span><\/i><i><span data-contrast=\"none\">is paper<\/span><\/i><i><span data-contrast=\"none\">&nbsp;<\/span><\/i><i><span data-contrast=\"none\">demonstrates how&nbsp;<\/span><\/i><i><span data-contrast=\"none\">industry leaders in fatty liver disease, NASH and fibrosis have&nbsp;<\/span><\/i><i><span data-contrast=\"none\">recognise<\/span><\/i><i><span data-contrast=\"none\">d<\/span><\/i><i><span data-contrast=\"none\">&nbsp;the quality of CN Bio\u2019s research and the reliability of our data<\/span><\/i><i><span data-contrast=\"none\">. We\u2019re excited to see this research published in Nature Metabolism,&nbsp;<\/span><\/i><i><span data-contrast=\"none\">a new and exciting journal for our field which wi<\/span><\/i><i><span data-contrast=\"none\">l<\/span><\/i><i><span data-contrast=\"none\">l<\/span><\/i><i><span data-contrast=\"none\">&nbsp;become highly impactful<\/span><\/i><i><span data-contrast=\"none\">.<\/span><\/i><i><span data-contrast=\"none\">\u201d<\/span><\/i><span data-ccp-props=\"{&quot;201341983&quot;:0,&quot;335559740&quot;:276}\">&nbsp;<\/span><\/p>\n<ol>\n<li data-leveltext=\"%1.\" data-font=\"Arial, Arial_MSFontService, sans-serif\" data-listid=\"5\" aria-setsize=\"-1\" data-aria-posinset=\"1\" data-aria-level=\"1\"><span data-contrast=\"none\">&#8216;Bone morphogenetic protein 8B promotes the progression of non-alcoholic steatohepatitis&#8217;<\/span><span data-contrast=\"none\">,&nbsp;<\/span><i><span data-contrast=\"none\">Nature Metabolism<\/span><\/i><i><span data-contrast=\"none\">,<\/span><\/i><span data-contrast=\"none\">&nbsp;<\/span><a href=\"https:\/\/www.nature.com\/articles\/s42255-020-0214-9\" target=\"_blank\" rel=\"noopener\"><span data-contrast=\"none\">https:\/\/www.nature.com\/articles\/s42255-020-0214-9<\/span><\/a><span data-contrast=\"none\">&nbsp;<\/span><span data-ccp-props=\"{&quot;134233279&quot;:true,&quot;201341983&quot;:0,&quot;335559740&quot;:276}\">&nbsp;<\/span><\/li>\n<\/ol>\n<p><span data-contrast=\"none\">CN Bio\u2019s NASH model is available as a fee-for-service offering,&nbsp;<\/span><span data-contrast=\"none\">performed and analysed&nbsp;<\/span><span data-contrast=\"none\">using<\/span><span data-contrast=\"none\">&nbsp;the Company\u2019s&nbsp;<\/span><span data-contrast=\"none\">PhysioMimix<\/span><span data-contrast=\"none\">\u2122&nbsp;<\/span><span data-contrast=\"none\">MPS. The offering&nbsp;<\/span><span data-contrast=\"none\">supports researchers in planning and optimi<\/span><span data-contrast=\"none\">s<\/span><span data-contrast=\"none\">ing clinical trial design, to prioriti<\/span><span data-contrast=\"none\">s<\/span><span data-contrast=\"none\">e pre-clinical candidates and integrate effects on different target cell types of the liver.<\/span><span data-ccp-props=\"{&quot;201341983&quot;:0,&quot;335559740&quot;:276}\">&nbsp;<\/span><span data-ccp-props=\"{&quot;201341983&quot;:0,&quot;335559740&quot;:276}\">&nbsp;<\/span><\/p>\n<p><span data-contrast=\"none\">For more information&nbsp;<\/span><span data-contrast=\"none\">about&nbsp;<\/span><span data-contrast=\"none\">CN Bio<\/span><span data-contrast=\"none\">\u2019s NASH drug discovery fee-for-service<\/span><span data-contrast=\"none\">,<\/span><span data-contrast=\"none\">&nbsp;please visit:<\/span><span data-contrast=\"none\">&nbsp;<\/span><a href=\"https:\/\/cn-bio.com\/nash-fee-for-service\/\"><span data-contrast=\"none\">https:\/\/cn-bio.com\/nash-fee-for-service\/<\/span><\/a><span data-contrast=\"none\">&nbsp;<\/span><span data-ccp-props=\"{&quot;201341983&quot;:0,&quot;335559740&quot;:276}\">&nbsp;<\/span><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Paper published in Nature Metabolism&nbsp;demonstrates&nbsp;novel pathway regulating the underlying mechanism of liver fibrosis&nbsp; Research&nbsp;harnesses&nbsp;CN&nbsp;Bio\u2019s&nbsp;liver-on-chip&nbsp;NASH disease model,&nbsp;to&nbsp;advance development of&nbsp;potential&nbsp;new medicines&nbsp;for&nbsp;liver fibrosis&nbsp; CN Bio, a leading&nbsp;cell culture&nbsp;company that has developed&nbsp;single and multi-organ microphysiological systems (MPS) that improve the accuracy and efficiency of drug discovery,&nbsp;today announced&nbsp;the publication of&nbsp;co-authored&nbsp;research led by researchers at the University of Cambridge in Nature [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_genesis_hide_title":false,"_genesis_hide_breadcrumbs":false,"_genesis_hide_singular_image":false,"_genesis_hide_footer_widgets":false,"_genesis_custom_body_class":"","_genesis_custom_post_class":"","_genesis_layout":"content-sidebar","footnotes":""},"categories":[6],"tags":[],"class_list":{"0":"post-3529","1":"post","2":"type-post","3":"status-publish","4":"format-standard","6":"category-press-release","7":"entry"},"acf":[],"featured_image_src":null,"featured_image_src_square":null,"author_info":{"display_name":"CN Bio","author_link":"https:\/\/cn-bio.com\/author\/cn-bio\/"},"_links":{"self":[{"href":"https:\/\/cn-bio.com\/wp-json\/wp\/v2\/posts\/3529","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cn-bio.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cn-bio.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cn-bio.com\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/cn-bio.com\/wp-json\/wp\/v2\/comments?post=3529"}],"version-history":[{"count":0,"href":"https:\/\/cn-bio.com\/wp-json\/wp\/v2\/posts\/3529\/revisions"}],"wp:attachment":[{"href":"https:\/\/cn-bio.com\/wp-json\/wp\/v2\/media?parent=3529"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cn-bio.com\/wp-json\/wp\/v2\/categories?post=3529"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cn-bio.com\/wp-json\/wp\/v2\/tags?post=3529"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}